PHARMACOECONOMIC EVLUATION OF 5-ASA APPLICATION IN LIGHT AND MEDIUM GRAVE DISSEMINATED (RECURRING) ULCERATIVE COLITIS

Inflammatory bowel diseases are chronic relapsing immune-mediated diseases affecting the gastrointestinal tract. The goal of therapy of ulcerative colitis (one of the IBD variants) is the achievement and maintenance of steroid-free remission, prevention of UC complications, prevention of surgeries and the timely use of surgical treatment when the process progresses and lifethreatening complications develop. It Is predominantly diagnosed in young people and leads to a significant reduction of quality of life. The peculiarity of the UC is its chronic recurrent course. Work on the choice of the most rational schemes of therapy continues goes on. New data from clinical studies on the efficacy and safety of modern methods of pharmacotherapy in addition to data on pharmacoepidemiology and pharmacoeconomics should help the medical community to develop the most optimal treatment strategies based on clinical and socio-economic factors. The standard therapy in the first phase is 5-ASA preparations, such as sulfasalazine and mesalazine. Given the efficacy and safety of each of these preparations it is possible to predict the frequency of transition of patients to more difficult treatment options systemic corticosteroids and biological agents arising in connection with this the possible side effects and additional economic load on the healing process. The article presents economic assessment of the use of two alternative first-line drugs for therapy - mesalazine and sulfasalazine; it shows a possible burden on the budget and subsequent benefit when switching to the most optimal treatment option.

1. Cho JH Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol, 2008 Jan 21, 14(3): 338-47.

2. Ивашкин В.Т. Клинические рекомендации российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению язвенного колита. 2017.

3. Шкурко Т. Воспалительные заболевания кишечника: проблемы, достижения и перспективы. 19 сентября 2016 г. http://www. niioz.ru/publications/pub20160919/.

4. Liverani E. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol, 2016 Jan 21, 22(3): 1017–1033.

5. Manser ChN. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J, 2016 Apr, 4(2): 281-7. doi: 10.1177/2050640615627533. Epub 2016 Jan 19.

6. Скалинская М.И. Пациент с язвенным коли-том: дифференцированный подход. СЗГМУ им. Мечникова. Доклад. Кафедра пропедевтики внутренних болезней, гастроэнтерологии и диетологии. Санкт-Петербург. 12 мая 2017 г.

7. Шелыгина Ю.А.. Клинические рекомендации. Колопроктология. М.: ГЭОТАР-Медиа, 2015. 528 с.